Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

MBCProject_4733_T1_RNA

— · A

0d79697d-51aa-5745-93be-2fd9cc5dd4f5

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
  • COAGULATION+0.390
  • APICAL_JUNCTION+0.380
  • CHOLESTEROL_HOMEOSTASIS+0.370
  • ADIPOGENESIS+0.330
  • MYOGENESIS+0.310
  • COMPLEMENT+0.300
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.300
  • ANGIOGENESIS+0.290
  • APICAL_SURFACE+0.270

Top 10 suppressed

  • MYC_TARGETS_V2-0.140
  • MYC_TARGETS_V1-0.040
  • PEROXISOME-0.010
  • UNFOLDED_PROTEIN_RESPONSE+0.000
  • ANDROGEN_RESPONSE+0.010
  • PANCREAS_BETA_CELLS+0.010
  • FATTY_ACID_METABOLISM+0.020
  • XENOBIOTIC_METABOLISM+0.020
  • BILE_ACID_METABOLISM+0.030
  • NOTCH_SIGNALING+0.030

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1718de66e-06d2-4c2c-8b2d-e40087c4340c
melanoma-umap@29
——0.873
2TCGA-60-2707-01A-01R-0851-07
lung-landscapes@6
—cohortSQ10.862
3b428d434-2904-4f67-a66f-b7928e2951e3
melanoma-umap@29
——0.842
4TCGA-BH-A18F-01A-11R-A12D-07
breast-umap@18
—A0.837
5SRR10900576
melanoma-umap@29
——0.833
6SRR33346953
bladder-landscape@3
——0.831
7EPT0508
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.827
8MDT-AP-0205
medullo-epn-umap@date-based
MedMedulloblastoma0.823
9b556b718-38cf-498d-94c7-4e240fe57d48
melanoma-umap@29
——0.815
1020060039.TNBC
breast-umap@18
—C0.814

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 46 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.430Inavolisib— uncovered
COAGULATION0.390Binimetinib— uncovered
APICAL_JUNCTION0.380Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.370Remibrutinib— uncovered
ADIPOGENESIS0.330Inavolisib— uncovered
MYOGENESIS0.310Inavolisib— uncovered
COMPLEMENT0.300Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.300Inavolisib— uncovered
ANGIOGENESIS0.290Remibrutinib— uncovered
APICAL_SURFACE0.270Temsirolimus— uncovered
ESTROGEN_RESPONSE_EARLY0.270Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.270Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.270Inavolisib— uncovered
TGF_BETA_SIGNALING0.250Inavolisib— uncovered
APOPTOSIS0.240Idelalisib— uncovered
HEDGEHOG_SIGNALING0.210Inavolisib— uncovered
IL2_STAT5_SIGNALING0.210Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.210Idelalisib— uncovered
UV_RESPONSE_UP0.200Idelalisib— uncovered
ALLOGRAFT_REJECTION0.190Idelalisib— uncovered